Aptevo Therapeutics Inc. (APVO): Total Liabilities
$9.81M
As of 2025-12-31
$8.48M
As of 2026-06-30
-15.5%
3-year compound annual growth
-23.3%
5-year compound annual growth
-12.9%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $9.81M | -9.4% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $10.84M | -14.1% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $12.62M | -22.3% | 2025-02-14, Balance as of period end |
| 2022-12-31 | $16.24M | -70.7% | 2024-03-05, Balance as of period end |
| 2021-12-31 | $55.38M | +49.9% | 2023-03-30, Balance as of period end |
| 2020-12-31 | $36.95M | -11.1% | 2022-03-24, Balance as of period end |
| 2019-12-31 | $41.57M | +12.1% | 2021-03-31, Balance as of period end |
| 2018-12-31 | $37.09M | +6.1% | 2020-03-25, Balance as of period end |
| 2017-12-31 | $34.97M | -15.3% | 2019-03-18, Balance as of period end |
| 2016-12-31 | $41.29M | n/a | 2018-03-13, Balance as of period end |
| 2016-06-30 | $36.27M | n/a | 2017-03-31, Balance as of period end |
| 2016-03-31 | $38.05M | n/a | 2017-03-31, Balance as of period end |
| 2015-12-31 | $39.15M | n/a | 2017-03-31, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Aptevo Therapeutics Inc. (APVO) | 2025-12-31 | $9.81M | -9.4% |
| TuHURA Biosciences, Inc. (HURA) | 2025-12-31 | $6.42M | +19.5% |
| Skye Bioscience, Inc. (SKYE) | 2025-12-31 | $8.29M | +79.7% |
| BeyondSpring Inc. (BYSI) | 2025-12-31 | $49.92M | +2.7% |
| Biofrontera Inc. (BFRI) | 2025-12-31 | $18.08M | +2.4% |
| Elicio Therapeutics, Inc. (ELTX) | 2025-12-31 | $24.23M | -38.7% |
| Neuphoria Therapeutics Inc. (NEUP) | 2026-06-30 | $4.11M | -57.1% |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $62.93M | +21.4% |
| Onconetix, Inc. (ONCO) | 2025-12-31 | $9.16M | -50.7% |
Compare APVO, HURA, SKYE, BYSI side by side · Screen every company in Pharmaceutical Preparations ↗